A Phase 1b, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Mipasetamab Uzoptirine (ADCT-601) Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With Selected Advanced Solid Tumors
ADC Therapeutics S.A. initiated a clinical trial to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of ADCT-601 in patients with advanced solid tumors, particularly focusing on sarcomas and pancreatic cancer. The study aimed to establish the recommended phase 2 dose and assess the drug's efficacy in combination with gemcitabine.
Indication: Advanced Solid Tumors
Modality: monoclonal antibody
Target: Mipasetamab Uzoptirine (ADCT-601)
Sponsor: ADC Therapeutics S.A.
Source URL: ClinicalTrials.gov
Source updated: May 22, 2025
Ingested: May 23, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Mipasetamab Uzoptirine (ADCT-601)
View original source fields
Condition raw: Advanced Solid Tumors
Condition normalized: Advanced Solid Tumors
Modality raw: Advanced Solid Tumors
Modality normalized: monoclonal antibody
Target raw: Mipasetamab Uzoptirine (ADCT-601)
Target normalized: Mipasetamab Uzoptirine (ADCT-601)